Resverlogix Corp.

Neurodegenerative Clinical & Scientific Advisory Board

Dr. Bengt Winblad, MD, PhD



Dr.  Winblad currently works at the Karolinska Institutet Alzheimer Disease Research Center in Huddinge, Sweden. His research interest mainly focuses on the basic mechanisms behind, as well as treatment of Alzheimer’s disease. Professor Winblad is also Chief Physician at Karolinska University in Huddinge since 1987.

He became an MD in 1971 and took his PhD in 1975 at the University of Umeå, Sweden, where he became a Docent in 1977 and Professor of Geriatric Medicine and Chief Physician in 1982. Professor Winblad has since been a guest professor at the Department of Psychiatry in Frankfurt and honorary professor at Beijing University, Wuhan University and Shanghai University in China. He has been involved in numerous university activities and has held various professional appointments, including that of member of the Advisory Committee for the Medical Research Council, Co-chair of the European Alzheimer’s Disease Consortium (EADC) and Chair of the Medical Scientific Advisory Panel of Alzheimer’s Disease International (ADI).

Professor Winblad has been a tutor for more than 150 PhD dissertations and has published more than 900 original publications in the field of gerontology/geriatrics/dementia research.

Dr. Jeffrey L. Cummings, MD, ScD



Dr. Cummings is Director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio. He is Camille and Larry Ruvo Chair of the Neurological Institute of Cleveland Clinic. The Lou Ruvo Center for Brain Health is a clinical care, translational research, and clinical trials enterprise specializing in care of patients with neurocognitive deficits and development of new therapies for neurodegenerative disorders.

Dr. Cummings is an experienced clinical trialist with expertise in clinical trial design and analysis, global trial implementation, and trial outcome measures. Dr. Cummings is the author of the Neuropsychiatric Inventory (NPI) which is the most commonly used tool for clinical trials characterizing behavioral disturbances in dementia syndromes.

Dr. Cummings completed Neurology residency and a Fellowship in Behavioral Neurology at Boston University, Boston, Massachusetts.  US training was followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London, England. Dr. Cummings was formerly Professor of Neurology and Psychiatry at UCLA, director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, and director of the Deane F. Johnson Center for Neurotherapeutics at UCLA. He is past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association. 

Dr. Cummings has authored or edited over 30 books and published 600 peer-reviewed papers.

Dr. Rada Koldamova, MD, PhD



Dr. Koldamova is an Associate Professor at the University of Pittsburgh, Pittsburgh, PA. She received her medical degree from Bulgarian Medical Academy, Sofia, Bulgaria in 1980 and her PhD from Bulgarian Academy of Sciences in 1994.

For the last 15 years Dr. Koldamova has been working on brain lipid metabolism related to Alzheimer's disease pathogenesis, and specifically the role of Abca1, mouse ApoE and ApoA-I using variety of biochemical and morphological approaches, as well as behavioral tests in complex transgenic and knockout model mice.

In 2003 Dr. Koldamova was the first to demonstrate that synthetic LXR agonists have rapid and pronounced therapeutic effect in AD model mice. She was also the first to report that global deletion of mouse Abca1 dramatically worsens AD phenotype in APP transgenic mice, which was independently confirmed by other research teams using different AD mouse models.

At present the work in her laboratory is concentrated on the role of lipoproteins in AD pathogenesis using transgenic mice expressing human ApoE isoforms.

Dr. Henrik Zetterberg, MD, PhD



Dr. Zetterberg is Professor of neurochemistry at the University of Gothenburg. He received his MD in 1998 and his PhD in 2003 both from the University of Gothenburg, Sweden. He was a Fulbright Scholar and research fellow in neurology at the Harvard Institutes of Medicine, Boston between 2004 and 2005.

With a background in molecular biology and clinical chemistry, Dr. Zetterberg has spent the last 10 years focusing on the development of biomarkers for Alzheimer’s disease and other brain disorders. His research is translational and the biomarkers are evaluated in cell and animal models, as well as in longitudinal studies of patients and healthy individuals. He has developed new diagnostic tests for Alzheimer’s disease, as well as new preclinical models, and has shown that amyloid pathology precedes tau pathology with around 5 years during the Alzheimer disease process in humans, that altered amyloid homeostasis in the brain is evident already in pre-symptomatic stages of the disease, and that the diagnostic usefulness of AD biomarkers decreases with age due to increased prevalence of preclinical Alzheimer neuropathology.

Dr. Zetterberg has 330 publications in PubMed.